Shionogi USA in the News
October 27, 2006 -- Shionogi Discontinues Development of S-5751, a Prostaglandin D2 Receptor Antagonist
August 14, 2006 -- GlaxoSmithKline and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor
July 10, 2006 -- Shionogi announces positive results from a Phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of Obesity
August 27, 2004 -- Shionogi acquires exclusive marketing and distribution rights for CEDAX® (ceftibuten) in the United States
October 23, 2001 -- Final agreement reached on GSK-Shionogi joint venture
July 24, 2001 -- GSK and Shionogi to enter global multi-product development and commercialization alliance
May 14, 2001 -- Establishment of Shionogi USA, Inc.
